Welcome to our dedicated page for SRX Global SEC filings (Ticker: SRXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SRx Health Solutions, Inc. (NYSE American: SRXH) files a range of SEC documents that together outline its evolving strategy, capital structure and planned combination with EMJ Crypto Technologies Inc. (EMJX). On this page, investors can review current reports on Form 8-K, registration statements on Form S-1 and S-1/A, and other filings that describe material agreements, financing transactions and listing-status developments.
In its 8-K filings, the company discloses the Share Exchange and Asset Transfer Agreement to acquire EMJX, CCC Crypto Corp. and related intellectual property assets, including technology that uses artificial intelligence to predict outcomes from data sets. These reports also cover stockholder approvals for a future name change to EMJX, Inc. and a planned ticker change to EMJX, amendments to the Certificate of Incorporation to increase authorized common shares, and the designation of Series A Convertible Preferred Stock with detailed rights and conversion terms.
SRXH’s registration statements on Form S-1 and S-1/A provide additional information on private placements of Series A Convertible Preferred Stock and warrants, as well as an equity line of credit arrangement with Keystone Capital Partners, LLC. These documents explain how the company may raise capital through the issuance of equity and equity-linked securities, and they discuss risks associated with ownership of its securities. Filings also address NYSE American continued listing standards, including notices of non-compliance related to stockholders’ equity and the exchange’s acceptance of the company’s plan to regain compliance.
Through Stock Titan, users can access these filings as they are made available on EDGAR and review them alongside AI-generated summaries that highlight key terms, structural features and risk considerations. This includes simplified explanations of complex documents such as 8-Ks describing material definitive agreements, S-1 registration statements detailing resale registrations and capital-raising arrangements, and governance-related amendments to the company’s charter and bylaws.
SRX Global Inc. (SRXH) entered into a secured financing transaction with CERo Therapeutics Holdings, Inc. through a Consolidated Senior Secured Promissory Note$5,666,108.77 of CERo’s prior convertible grid notes and permits additional advances of up to $6,000,000, for a maximum aggregate loan of $11,666,108.77. On August 27, 2026, SRX Global funded an initial advance of $775,665.00.
The Note bears interest at 10% per annum, increasing during an Event of Default to up to 24.99% per annum, and currently matures on October 15, 2026, with SRX Global able to extend for up to four 30‑day periods. The debt is secured by a first‑priority pledge of all capital stock of CERo’s wholly owned subsidiary and a security interest in substantially all of the subsidiary’s assets, including intellectual property and assets related to CER-1236, and is guaranteed by the subsidiary.
SRX Global Inc. (SRXH) entered into a Securities Purchase Agreement with accredited investors for a private placement of its Series C Convertible Preferred Stock. The company issued 3,579 Series C shares for a purchase price of $2,862,500, paid by assigning Convertible Grid Promissory Notes of CERO Therapeutics Holdings, Inc. with an aggregate original principal of $2,812,500.
SRX Global has designated 4,000 Series C shares, each with a $1,000 stated value, ranking senior to common stock and pari passu with existing Series A and B preferred. The shares are convertible into common stock at a fixed Conversion Price of $2.1888 per share, with alternative conversion prices tied to 95% or 90% of the lowest five-day volume-weighted average price after stockholder approval and upon certain Triggering Events. The company may redeem all Series C shares in cash at 125% of a defined conversion-based value and must reserve at least 200% of the common shares needed for conversion.
In connection with the transaction, SRX Global entered into a Registration Rights Agreement requiring it to register for resale the common stock issuable upon conversion of the Series C Preferred Stock and upon exercise of related warrants. The securities were issued in an unregistered private offering under Section 4(a)(2) and Rule 506 of Regulation D.
SRX Global Inc. (SRXH) reported fiscal third quarter 2026 results highlighted by stronger revenue growth, narrower losses and a highly liquid balance sheet. Net sales rose 27% year over year to $3.4 million, while operating loss improved 63% to $3.2 million and net loss from continuing operations improved 40% to $4.1 million. Adjusted EBITDA loss improved 35% year over year to $1.6 million.
As of June 30, 2026, SRX Global reported $65.2 million in current assets and $2.4 million in total liabilities, with no debt outstanding. Net asset value was approximately $62.9 million or $3.22 per common share, above preliminary estimates of $60.0 million and $3.07 per share; the company also held $36.7 million in cash, cash equivalents and restricted cash.
The company completed the acquisition of EMJX, an AI-enabled digital-asset treasury platform, and reported hypothetical model results showing a maximum drawdown of about 10.6% versus 28–58% for benchmark comparators since February 2026. SRX approved a 10 million share repurchase program and declared a $0.05 per-share one-time dividend (about $1.3 million), while continuing to post sizable losses, including a nine-month net loss from continuing operations of $19.1 million.
SRX Global Inc. (SRXH) reported higher net sales but continued losses for the three and nine months ended June 30, 2026, while transforming its business and balance sheet. Net sales from continuing operations rose to $3.4 million from $2.7 million a year earlier, and to $9.6 million for the nine-month period. Loss from continuing operations improved to $4.1 million from $6.9 million in the quarter, and to $19.1 million for nine months, but the company remains meaningfully unprofitable.
Cash and cash equivalents increased to $36.7 million (including restricted cash) from $1.3 million, and total assets reached $145.4 million, driven largely by an $80.0 million asset acquisition of EMJX, an AI-driven digital-asset treasury management platform, recorded as indefinite-lived intangible assets. Total liabilities were only $2.4 million, with prior convertible debt eliminated, resulting in stockholders’ equity of $143.0 million. The company now operates two segments: the legacy Halo pet products business and the new EMJX platform, and holds $2.1 million of Ethereum and other financial investments, introducing digital-asset and trading-related volatility. NYSE American halted trading on June 23, 2026 due to low share price, and a 1‑for‑60 reverse stock split became effective July 6, 2026. Management states it sees no material uncertainties about the company’s ability to continue as a going concern over the next 12 months.
SRX Global Inc. filed an amended report to correct a typographical error, clarifying that Carolina Martinez serves as Chief Financial Officer, not Chief Executive Officer.
The company describes a private placement under a Securities Purchase Agreement allowing purchase of up to 10,000 shares of Series B convertible preferred stock and accompanying warrants for up to $8.0 million. An initial March 16, 2026 closing involved 5,660 Series B shares and 22,237,666 warrants for approximately $4.528 million in cash proceeds. At an Additional Closing on July 27, 2026, investors purchased 4,340 Series B shares and 284,156 warrants, generating approximately $3.472 million in cash. Warrant numbers reflect a previously announced 60-for-1 reverse stock split effective July 2, 2026. These securities were issued without registration in reliance on Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
SRX Global Inc. reported an additional private placement closing under a Securities Purchase Agreement originally dated March 16, 2026. The agreement permits the sale of up to 10,000 shares of Series B convertible preferred stock for an aggregate purchase price of up to $8.0 million, together with accompanying warrants.
At the initial March 16, 2026 closing, the company sold 5,660 Series B shares and 22,237,666 warrants for cash proceeds of approximately $4.528 million. On July 27, 2026, at an Additional Closing, it sold 4,340 Series B shares and 284,156 warrants for approximately $3.472 million in cash, with the warrant number reflecting a 60-for-1 reverse stock split effective July 2, 2026.
The securities were issued in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D. These securities are restricted and may not be offered or sold in the United States absent registration or an applicable exemption.
SRX Global Inc. entered into a Limited Waiver and Consent Agreement with the Required Holders under its existing Securities Purchase Agreement that allows the company to return capital to common stockholders while that financing remains in place. The original agreement permits accredited investors to purchase up to 10,000 shares of Series B convertible preferred stock for an aggregate purchase price of up to $8.0 million in one or more closings.
Under the Waiver, the Required Holders consent to SRX Global’s plan to declare and pay a one-time cash dividend of $0.05 per share on common stock outstanding, payable on August 3, 2026 to stockholders of record at the close of business on July 22, 2026. They also consent to a stock repurchase plan under which the company may repurchase up to the lesser of 10,000,000 shares of common stock or 50% of the issued and outstanding common stock at any given time, for an aggregate purchase price not to exceed $20,000,000, during the period ending July 7, 2027.
SRX Global Inc. has filed a prospectus supplement covering the resale by existing holders of up to 3,125,752 shares of common stock, including shares issuable from prior PIPE financings, the SRx Canada acquisition, service-based issuances and a share exchange, all adjusted for a 1‑for‑60 reverse stock split effective July 6, 2026.
The company recently closed its acquisition of EMJ Crypto Technologies and related entities, issuing 268,346,659 common shares, 117,268,196 Exchangeable Shares and Pre‑Funded Warrants for 44,368,530 shares under a previously declared‑effective Form S‑4, and changed its name from SRx Health Solutions to SRX Global while keeping the SRXH ticker.
Management reports preliminary net asset value of approximately $60 million, or $3.07 per share, with approximately $40 million in cash, more than $15 million in short‑term investments, no debt and approximately 19,517,834 common shares outstanding post‑split. The board has approved a one‑time $0.05 per‑share cash dividend (about $1 million aggregate) and authorized a share‑repurchase program of up to 10 million shares or $20 million through July 9, 2027. SRX also highlights a paper‑traded EMJX strategy that returned 24.8% from February 11 to July 10, 2026, versus a 4.2% decline in bitcoin over the same period. On July 15, 2026 NYSE American notified SRX that it had regained compliance with all continued listing standards.
SRX Global Inc. filed a prospectus supplement covering the resale, from time to time, of up to 41,781,566 shares of common stock by Keystone Capital Partners under a Common Share Purchase Agreement. The company will not receive proceeds from Keystone’s resales, though it may receive cash when it elects to sell shares to Keystone; the registered amount reflects the completed 1-for-60 reverse stock split effective July 6, 2026.
SRX Global recently closed its acquisition of EMJ Crypto Technologies and related entities, issuing an aggregate of 268,346,659 common shares, 117,268,196 exchangeable shares and 44,368,530 pre-funded warrants, and changed its name from SRx Health Solutions, Inc. to SRX Global Inc. Following the July 6 share consolidation, the company reports preliminary June 30, 2026 figures of approximately $40 million in cash, more than $15 million in short‑term investments, estimated net asset value of about $60 million or $3.07 per share, and approximately 19,517,834 shares outstanding, with no debt.
The board approved a one-time cash dividend of $0.05 per share (about $1 million in total) and authorized a share repurchase program for up to 10 million shares, or up to 50% of shares outstanding, with up to $20 million allocated. Management highlights EMJX’s AI‑driven, paper‑traded strategy, which it reports returned 24.8% from February 11 to July 10, 2026 versus Bitcoin at -4.2%, and states an intention to deploy real capital into this framework. After the reverse split, NYSE American confirmed SRX Global is back in compliance with its continued listing standards.
SRX Global Inc. reports that, on July 15, 2026, NYSE American notified the company it is back in compliance with all NYSE American LLC continued listing standards set forth in Part 10 of the NYSE American Company Guide. The company has resolved the continued listing deficiency related to Section 1003(a)(i) and (ii), which had been cited in an NYSE letter dated October 14, 2025.
According to NYSE Regulation, SRX Global’s compliance indicator “.BC” will no longer be disseminated, and the company will be removed from the NYSE American list of noncompliant issuers on the exchange’s website. SRX describes itself as an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies and strategic assets.